Glisoxepide
Names | |
---|---|
IUPAC names
N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl) phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide | |
Identifiers | |
25046-79-1 | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL2106618 |
ChemSpider | 30380 |
DrugBank | DB01289 |
ECHA InfoCard | 100.042.329 |
KEGG | D07118 |
PubChem | 32778 |
UNII | H7SC0I332I |
| |
| |
Properties | |
C20H27N5O5S | |
Molar mass | 449.52388 g/mol |
Pharmacology | |
A10BB11 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Glisoxepide (INN) is an orally available anti-diabetic drug from the group of sulfonylureas.[1] It belongs to second-generation sulfonylureas.[2]
References
- ↑ Haupt E, Köberich W, Beyer J, Schöffling K (December 1971). "Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects". Diabetologia. 7 (6): 449–54. doi:10.1007/bf01212061. PMID 5004178.
- ↑ Loubatières, A; Ribes, G; Mariani, MM; Alric, R. "Pharmacological Comparison Between Tolbutamide and Two Second Generation Hypoglycemic Sulfonylureas (Glibenclamide and Glisoxepide)". Acta diabetologica latina. 10 (2): 261–82. doi:10.1007/bf02590661. PMID 4200420.
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.